Sanwa Kagaku Obtains Gout Drug Rights From Fuji Yakuhin
This article was originally published in PharmAsia News
Executive Summary
Nagoya-based drug maker Sanwa Kagaku signed an agreement Oct. 8 with Fuji Yakuhin to develop and commercialize hyperuricemia and gout drug candidate FYX-051